Skip to main content

Table 3 Characteristics related to ART

From: The impact of the COVID-19 pandemic on people living with HIV: a cross-sectional study in Caracas, Venezuela

Current ART, n (%)

n = 202

 2 NRTI + INSTI (TLD)

184 (91)

 2 NRTI without TDF + INSTI

18 (8.9)

Previous ART regimen, n (%)

n = 155

 2 NRTIs + INSTI

14 (9.0)

 2 NRTIs + PI

60 (38.7)

 2 NRTIs + NNRTI

78 (50.3)

 Other

3(1.9)

Post-ART viral load, n (%)

n = 202

 ≤ 20

98 (48.5)

 21–199

33 (16.3)

 200–999

4 (2.0)

 ≥ 1000

2 (1.0)

 Not available

65 (32.2)

CD4+post-ART, n (%)

n = 202

 ≤ 200

6 (2.9)

 201–350

3 (1.5)

 351–500

4 (2.0)

 ≥ 501

9 (4.5)

Not available

180 (89.1)

Weekly treatment adherence (tablet ingested/prescribed)

n = 202

 4/7

1 (0.5)

 5/7

4 (2.0)

 6/7

27 (13.4)

 7/7

170 (84.1)

  1. NRTIs: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; INSTI: integrase strand transfer inhibitors; TLD: dolutegravir + lamivudine + tenofovir disoproxil fumarate; TDF: tenofovir disoproxil fumarate; ART: antiretroviral treatment